Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tracking a psoriasis Drug's Real-World performance in kids

NCT ID NCT06142357

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study is observing children and teens (ages 6-17) with moderate-to-severe plaque psoriasis who are starting treatment with the drug secukinumab. The main goal is to see how long patients stay on the medication, how effective it is at clearing their skin, and what side effects they experience. Researchers will follow these patients for up to two years during their regular doctor visits to collect this real-world information.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MODERATE TO SEVERE PLAQUE PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Novartis Investigative Site

    Chelyabinsk, 454048, Russia

  • Novartis Investigative Site

    Grozny, 364022, Russia

  • Novartis Investigative Site

    Izhevsk, 426009, Russia

  • Novartis Investigative Site

    Kazan', 420012, Russia

  • Novartis Investigative Site

    Kemerovo, 650025, Russia

  • Novartis Investigative Site

    Moscow, 105007, Russia

  • Novartis Investigative Site

    Moscow, 117513, Russia

  • Novartis Investigative Site

    Moscow, 119296, Russia

  • Novartis Investigative Site

    Moscow, 119435, Russia

  • Novartis Investigative Site

    Mytishchi, 141009, Russia

  • Novartis Investigative Site

    Nizhny Novgorod, 603950, Russia

  • Novartis Investigative Site

    Rostov-on-Don, 344022, Russia

  • Novartis Investigative Site

    Tolyatti, 445846, Russia

  • Novartis Investigative Site

    Tula, 300053, Russia

  • Novartis Investigative Site

    Ufa, 450000, Russia

  • Novartis Investigative Site

    Yakutsk, 677000, Russia

Conditions

Explore the condition pages connected to this study.

MODERATE TO SEVERE PLAQUE PSORIASIS